A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated with Chronic Obstructive Pulmonary Disease
A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuous Intravenous Infusion in Subjects with Acute Ischemic Stroke and Measurable Penumbra on MRI.
100 项与 Asubio Pharmaceutical, Inc. 相关的临床结果
0 项与 Asubio Pharmaceutical, Inc. 相关的专利（医药）
100 项与 Asubio Pharmaceutical, Inc. 相关的药物交易
